$ASND News

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia

Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed

Ascendis Pharma (ASND) Authorizes $400M Share Buyback

Ascendis Pharma: Back To Full Independence

Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback

Ascendis Announces Planned $400 Million Share Repurchase Program

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Ascendis Pharma Authorizes Up To $400M Share Repurchase Program